Finance

Lists
688068:SHA
Beijing Hotgen Biotech Co Ltd
CNÂ¥96.87
+0.81%
(+0.78) 1D
Sep 22, 11:29:56 AM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 688068...
Open
CNÂ¥94.00
High
CNÂ¥99.73
Low
CNÂ¥93.61
Mkt. cap
8.19B
Avg. vol.
3.14M
Volume
3.51M
52-wk high
CNÂ¥214.78
52-wk low
CNÂ¥73.44
EPS
-CNÂ¥3.00
No. of employees
946
Open
CNÂ¥94.00
High
CNÂ¥99.73
Low
CNÂ¥93.61
Mkt. cap
8.19B
Avg. vol.
3.14M
Volume
3.51M
52-wk high
CNÂ¥214.78
52-wk low
CNÂ¥73.44
EPS
-CNÂ¥3.00
No. of employees
946
Profile
Hotgen Biotech, often simply referred to as Hotgen, is a Chinese biological technology company founded in 2005. It focuses on the manufacture of in-vitro diagnostic instruments and reagents. In September 2019, the company was listed on the Shanghai Stock Exchange. During the novel coronavirus pandemic, it specialized in making 2019-nCoV antigen diagnostic products, which obtained EU CE certification. Hotgen was formerly a constituent of the STAR 50 Index. Headquartered in Beijing, it also established presences in foreign markets, such as the United Kingdom, France, and Germany. The net profit of the company in 2021 exceeded 2.3 billion yuan, an increase of more than sixteen times from the previous year. In 2022, its RAT kits were distributed free of charge by the Hong Kong Government to the public. In November 2023, it attended the MEDICA Trade Fair in Düsseldorf. Wikipedia
About Beijing Hotgen Biotech Co Ltd
CEO-
Employees946
FoundedJun 23, 2005
Headquarters-
SectorHealth care
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
105.80M
95.17M
116.03M
151.72M
Cost of goods sold
49.91M
40.31M
55.11M
36.53M
Cost of revenue
49.91M
40.31M
55.11M
36.53M
Research and development expenses
19.65M
94.81M
49.10M
46.03M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
83.78M
99.31M
97.60M
127.34M
Operating expense
98.59M
204.82M
143.51M
173.54M
Total operating expenses
148.50M
245.13M
198.62M
210.07M
Operating income
-42.70M
-149.96M
-82.59M
-58.35M
Other non operating income
-273.76K
2.19M
-2.39M
-19.70M
EBT including unusual items
-20.92M
-155.14M
-82.67M
-76.94M
EBT excluding unusual items
-28.82M
-122.01M
-69.59M
-74.79M
Income tax expense
4.59M
-6.98M
-5.78K
-796.34K
Effective tax rate
-21.96%
4.50%
0.01%
1.03%
Other operating expenses
-5.37M
6.99M
-2.96M
-46.87K
Net income
-24.96M
-107.09M
-68.06M
-58.07M
Net profit margin
-23.59%
-112.52%
-58.66%
-38.27%
Earnings per share
-
-
-
-
Interest and investment income
14.98M
35.99M
15.44M
3.26M
Interest expense
-289.66K
-7.96M
-46.88K
-
Net interest expenses
14.69M
28.03M
15.39M
3.26M
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.62M
-129.90M
-62.53M
-40.06M
Gain or loss from assets sale
601.43K
-579.43K
-
6.83K
AI content may include mistakes. Learn more
Google apps